ALK B ALK-ABELLO A/S

Henriette Mersebach to step down as ALK’s head of R&D

Henriette Mersebach to step down as ALK’s head of R&D

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Henriette Mersebach will step down as Executive Vice President, Research and Development, and as a member of the Board of Management, effective 23 February 2026. It has also been agreed that she will support the transition and assist with handover as needed.

By mutual agreement, the CEO, Board of Directors and Henriette Mersebach have decided that it is the right time to appoint a new head of R&D with a different profile to advance ALK’s innovation efforts under the Allergy+ strategy. The aim of these efforts is to balance core‑business growth with expansion into adjacent allergy therapy areas via the internal pipeline, partnerships, and business development & licensing.

All ongoing clinical development programmes will continue unchanged.

Peter Halling, President & CEO, said: “On behalf of the Board of Directors and ALK, I would like to thank Henriette for her contributions over the past three years. She and her team secured important regulatory approvals, including for our paediatric treatments, and advanced our peanut allergy programme, among other achievements. We are progressing according to plan against the short‑term targets set out in our Allergy+ strategy, as detailed in today’s annual report. As we enter the next phase, we believe appointing a new leader with a different profile is the right step to drive our ambitious innovation strategy.”

ALK has initiated a search for a new head of R&D. Furthermore, ALK has appointed Henrik Jacobi – ALK’s former Head of R&D – as special advisor to the CEO and Executive Leadership Team. Henrik will assist with further evolving ALK’s innovation model and other scientific projects.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy. ALK's activities cover the entire value chain of developing, sourcing, producing, and marketing a diversified portfolio of products for diagnosing and treating respiratory allergies and severe allergic reactions (anaphylaxis) in both children and adults. Headquartered in Denmark, ALK employs around 2,700 people worldwide and is listed on Nasdaq Copenhagen (Nasdaq: ALK B). Visit us at

Attachment



EN
20/02/2026

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
02/23/26 February 23, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Ordinær generalforsamling i ALK-Abelló A/S den 16. marts 2026

Ordinær generalforsamling i ALK-Abelló A/S den 16. marts 2026 Ordinær generalforsamling i ALK-Abelló A/S (ALKB:DC / Nasdaq Copenhagen: ALK B) finder sted mandag den 16. marts 2026 kl. 16.00 hos ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm i henhold til vedhæftede indkaldelse med bestyrelsens fuldstændige forslag, som fremsættes på generalforsamlingen. ALK-Abelló A/S For yderligere oplysninger kontakt venligst:Investor Relations: Per Plotnikof, tlf. 4574 7527, mobil 2261 2525Presse: Maiken Riise Andersen, tlf. 5054 1434 Om ALKALK er en global, specialiseret medicinalvirksomhed med fok...

February 20, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Annual General Meeting in ALK-Abelló A/S on 16 March 2026

Annual General Meeting in ALK-Abelló A/S on 16 March 2026 The Annual General Meeting of ALK-Abelló A/S (ALKB:DC / Nasdaq Copenhagen: ALK B) will take place on Monday, 16 March 2026 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached. ALK-Abelló A/S For further information, contact: Investor Relations: Per Plotnikof, tel. , mobile Media: Maiken Riise Andersen, tel. About ALKALK is a global specialty pharmaceutical company focused on allergy. ALK's activiti...

February 20, 2026 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
02/20/26 February 20, 2026 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Henriette Mersebach fratræder som forskningsdirektør i ALK

Henriette Mersebach fratræder som forskningsdirektør i ALK ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) har i dag meddelt, at Henriette Mersebach fratræder som Executive Vice President, Research and Development, og som medlem af direktionen med virkning fra 23. februar 2026. Det er aftalt, at hun bistår med overlevering efter behov. Efter gensidig aftale har den administrerende direktør, bestyrelsen og Henriette Mersebach aftalt, at nu er det rette tidspunkt at udpege en ny forskningsdirektør med en anden profil for at styrke ALK’s innovationsindsats under Allergy+-strategien. Formålet er at b...

February 20, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch